Cargando…

Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises several clinical entities with diverse clinical presentations, outcomes, and nonunifying pathogenesis. AAV has a clear potential for relapses, and shows unpredictable response to treatment. Cyclophosphamide-based therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lenert, Aleksander, Lenert, Petar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294650/ https://www.ncbi.nlm.nih.gov/pubmed/25609919 http://dx.doi.org/10.2147/DDDT.S67264

Ejemplares similares

Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab
por: Kowalczyk-Quintas, Christine, et al.
Publicado: (2018)

BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis
por: Prieto-Peña, Diana, et al.
Publicado: (2021)

The Role of Clinical Features and Serum Biomarkers in Identifying Patients with Incomplete Lupus Erythematosus at Higher Risk of Transitioning to Systemic Lupus Erythematosus: Current Perspectives
por: Sternhagen, Erin, et al.
Publicado: (2022)

Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
por: Lenert, Aleksander, et al.
Publicado: (2017)

Author Correction: BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis
por: Prieto-Peña, Diana, et al.
Publicado: (2021)

B cell alterations during BAFF inhibition with belimumab in SLE
por: Ramsköld, Daniel, et al.
Publicado: (2018)

Data for the crystal structure of APRIL–BAFF–BAFF heterotrimer
por: Maskos, Klaus, et al.
Publicado: (2015)

Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus
por: Lenert, Petar S
Publicado: (2006)

The BAFF-APRIL System in Cancer
por: Ullah, Md Ashik, et al.
Publicado: (2023)

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases
por: Nakayamada, Shingo, et al.
Publicado: (2016)

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
por: McClure, Mark E., et al.
Publicado: (2023)

April and Baff Connect Autoimmunity and Cancer
por: Ware, Carl F.
Publicado: (2000)

Classification, Mechanisms of Action, and Therapeutic Applications of Inhibitory Oligonucleotides for Toll-Like Receptors (TLR) 7 and 9
por: Lenert, Petar S.
Publicado: (2010)

BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus
por: Shin, Woori, et al.
Publicado: (2018)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity
por: Vincent, Fabien B., et al.
Publicado: (2013)

Diagnostic Dilemma of Disseminated Histoplasmosis Mimicking Hemophagocytosis Lymphohistiocytosis in Patient with Rheumatoid Arthritis on Anti-TNF Therapy: Case Report and Review of the Literature
por: Suman, Saurav, et al.
Publicado: (2019)

BAFF and APRIL expression as an autoimmune signature of membranous nephropathy
por: Han, Seung Seok, et al.
Publicado: (2017)

Hypopyon complicating the course of anterior uveitis in a patient with Behcet's syndrome
por: Singh, Namrata, et al.
Publicado: (2016)

Characterization of BAFF and APRIL subfamily receptors in rainbow trout (Oncorhynchus mykiss). Potential role of the BAFF / APRIL axis in the pathogenesis of proliferative kidney disease
por: Granja, Aitor G., et al.
Publicado: (2017)

Management of ANCA-associated vasculitis: Current trends and future prospects
por: Hamour, Sally, et al.
Publicado: (2010)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-associated vasculitis of the appendix
por: Leaver, Phillip J, et al.
Publicado: (2019)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Wallace, Zachary S., et al.
Publicado: (2019)

Involvement of BAFF and APRIL in Resistance to Apoptosis of Acute Myeloid Leukemia
por: Bolkun, Lukasz, et al.
Publicado: (2016)

APRIL and BAFF: novel biomarkers for central nervous system lymphoma
por: Mulazzani, Matthias, et al.
Publicado: (2019)

BAFF and APRIL counterregulate susceptibility to inflammation-induced preterm birth
por: Doll, Jessica R., et al.
Publicado: (2023)

New treatment options for lupus – a focus on belimumab
por: Chiche, Laurent, et al.
Publicado: (2012)

Frailty assessment in ANCA-associated vasculitis: current evidence and remaining uncertainties
por: Wang, Choon Ying, et al.
Publicado: (2022)

Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia
por: Tandler, Claudia, et al.
Publicado: (2020)

Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
por: Goel, Ruchika, et al.
Publicado: (2021)

Progress in treatment of ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2012)

Animal Models of ANCA Associated Vasculitis
por: Shochet, Lani, et al.
Publicado: (2020)

Eye involvement in ANCA positive vasculitis
por: Macarie, Sorin Simion, et al.
Publicado: (2020)

Mechanisms of thrombosis in ANCA-associated vasculitis
por: Misra, Durga Prasanna, et al.
Publicado: (2021)

Granulomatous Inflammation in ANCA-Associated Vasculitis
por: Müller, Antje, et al.
Publicado: (2021)

Complement Inhibition in ANCA-Associated Vasculitis
por: Tesar, Vladimir, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cj985mkcj6q75nitj563i6kmqd